Načítá se...
Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer
Castrate-resistant prostate cancer (CRPC) is a disease where survival is poor and treatment is challenging. Over the past 3 years, significant advances in the field have been made with US Food and Drug Administration approval of new drugs for patients with CRPC. However, despite the presence of new...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2014
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3928061/ https://ncbi.nlm.nih.gov/pubmed/24600234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S53524 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|